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Abstract
Objective: To explore whether there are gender differences in the number of GP recorded cases, the probability of survival
and consulting pattern prior to diagnosis amongst patients with three non-sex-specific cancers.
Design: Cross sectional study.
Setting: UK primary care.
Subjects: 12,189 patients aged 16 years or over diagnosed with colorectal cancer (CRC), 11,081 patients with lung cancer
and 4,352 patients with malignant melanoma, with first record of cancer diagnosis during 1997–2006.
Main outcome measures: Cancer cases recorded in primary care; probability of survival following diagnosis; and number of
GP contacts within the 24 months preceding diagnosis.
Results: From 1997–2006, overall rates of GP recorded CRC and lung cancer cases recorded were higher in men than in
women, but rates of malignant melanoma were higher in women than in men. Gender differences in survival were small;
49% of men and 53% of women survived at least 5 years following CRC diagnosis; 9% of men and 12% of women with lung
cancer, and 77% of men and 86% of women with malignant melanoma. The adjusted male to female relative hazard ratio of
death in all patients was 1.20 (95%CI 1.13–1.30), 1.24 (95%CI 1.16–1.33) and 1.73 (95%CI 1.51–2.00) for CRC, lung cancer and
malignant melanoma respectively. However, gender differences in the relative risk were much smaller amongst those who
died during follow-up. For each cancer, there was little evidence of gender difference in the percentage who consulted and
the number of GP contacts made within 24 months prior to diagnosis.
Conclusions: This study found that patterns of consulting prior to cancer diagnosis differed little between two genders,
providing no support for the hypothesis that gender differences in survival are explained by gender differences in
consultation for more serious illness, and suggests the need for a more critical view of gender and consultation.
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Introduction
Women live longer than men in almost all countries [1]. Both
biological and social explanations have been posited for this
gender difference [2]. Bio-medical research has focused on
anatomy, physiology and the role of sex hormones in explaining
differences between health outcomes in men and women [3],
whilst sociological research has emphasised behavioural and
cultural factors. In particular, differences in health behaviours
such as smoking, heavy drinking and poor diet appear to explain
much of the gender differences in mortality apparent over recent
decades [4,5]. Well documented gender differences in the
frequency of contact with primary health care services, in
particular in early adult life and middle age, based both on self-
reported [6] and routinely collected consultation data [7,8], have
led many to suggest that differences in health service use are also
an important contributor to gender differences in mortality. Such
arguments are bolstered by qualitative studies which have
documented men’s apparent reluctance to consult [9,10]. Despite
recent reviews which challenge this view [11,12], there remains a
widespread assumption that men are always more reluctant to
consult and that, by extension, gender differences in the propensity
to consult may partly explain gender differences in longevity
(through delayed consultation leading to later diagnosis and
therefore decreased opportunities for effective treatment and
reduced survival in men). However, there is a paucity of research
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comparing consultation patterns in men and women with similar
underlying (and serious) morbidity to support or refute the claim.
Here we present an analysis of consultations made by cancer
patients as recorded in a large general practice database,
examining consultation pattern amongst men and women in the
24 months prior to a recorded diagnosis with three non-sex specific
cancers, namely colorectal cancer, lung cancer and malignant
melanoma.
In the UK, as in other parts of Europe, men are at greater risk
of being diagnosed with, and dying from, nearly all non-sex
specific cancers [13], although gender patterns have changed over
time. Between 1975 and 2010, cancer incidence rates in the UK
increased by 22% in men and 42% in women but cancer mortality
decreased more rapidly in men than women (by 28% and 16%
respectively). These trends partly reflect changing patterns of
smoking by gender in earlier decades. In 2010, 324,579 new cases
of cancers (excluding non-melanoma skin cancer) were diagnosed
in the UK, including 163,904(50.5%) in men and 160,675 (49.5%)
in women. There were 82,481 male deaths and 74,794 female
deaths from cancer in the same year [13,14]. Of non-sex specific
cancers, lung cancer is the most common cause of death for both
genders, accounting for 24% of cancer deaths in men and 21% in
women, and colorectal cancer (CRC) is the second biggest cause of
cancer death (accounting for 11% and 10% of cancer deaths in
men and women respectively) [15,16]. Between the ages of 15 and
64 years, malignant melanoma is one of the few non-sex specific
cancers to be more commonly diagnosed in women than men,
although the gender pattern is reversed at older ages [13].
If gender differences in consulting are important in explaining
gender differences in mortality, we should expect that men would
consult primary health care services less and that they would
consult later with symptoms that could be indicative of major
contributors to overall death rates, such as these common forms of
cancer. Analyses of general practice consultation data do indeed
provide evidence that women consult more on average than men
overall, particularly in early adulthood and mid-life [6,8]. However,
the evidence on whether there are gender differences in patterns of
consultation prior to diagnosis with colorectal cancer is mixed. An
early North American study showed a significantly longer delay
from first noting symptoms to diagnosis in women rather than men,
contradicting widespread assumptions, and a longer delay for
women between first consultation for the symptoms and diagnosis
(‘‘physician delay’’) [17], whilst a recent population-based survey
reported no gender differences in seeking help for cancer
symptoms such as rectal bleeding [18]. Other studies have noted
men’s greater likelihood of delaying help-seeking following the
development of CRC symptoms. For example, an Australian study
of people with CRC found that a higher percentage of men than
women (31% and 10% respectively) waited more than 3 months
from initial symptoms to their first visit to their doctors [19].
Studies of gender differences in time to consultation for symptoms
of lung cancer are also contradictory. An early American study
suggested that women experienced a longer delay than men
between first recognition of symptoms and lung cancer diagnosis,
although the absolute difference between the two was small [20],
but a Scottish study found no gender differences in time to
consultation [21] and a recent pilot study in the UK found no
difference between men and women in terms of symptom times
and presentation to the GP [22].
Given this background, this paper presents analyses of routinely
collected data from the Health Improvement Network, a large UK
primary care database. Our aim is to assess whether there is any
evidence to support the hypothesis that gender differences in
patterns and timing of consulting for symptoms of non-sex specific
cancers (i.e. male ‘reluctance’ to consult until later stages of
diseases) could plausibly account for gender differences in
mortality. We approach this question in three stages. First, we
examine gender-specific rates of three cancers (CRC, lung cancer
and malignant melanoma) by age and deprivation levels, to allow
comparison of the gender patterns in cancer rates observed in
participating general practices within THIN with other national
sources. Secondly, since stage of cancer is not reliably recorded in
the routine data source, we investigate whether there are gender
differences in survival following diagnosis with these three non-sex
specific cancers; if men were presenting at a later stage, we would
expect that their survival, especially in the first few years after
diagnosis would be worse. Thirdly, we query whether there are
gender differences in the number of GP contacts within the 24
months preceding diagnosis. Our hypothesis is that, if gender
differences in the use of health services are an important
contributor to gender differences in mortality, we would expect
poorer survival following diagnosis in men, particularly in the
years soonest after diagnosis, and marked gender differences in the
number and time of patients’ contacts with their GPs prior to
diagnosis.
Methods
Data source
UK general practices are usually the first point of contact for
UK patients using the National Health Service (NHS). The Health
Improvement Network (THIN) database is one of the largest
primary care data sources, consisting of electronic records for over
11 million patients from more than 500 general practices in the
UK. THIN contains anonymised patient data directly extracted
from practices using the Vision general practice system and is a
clinical database which includes information on patients’ year of
birth, gender, post code, registration details, clinical symptoms,
medical diagnoses, laboratory tests, referrals and prescriptions, at
every primary health care service contact. Participating practices
are broadly representative of UK general practice [23,24]. The
database also includes information on individual patients’ socio-
economic status (measured by quintiles of Townsend deprivation
score based on 2001 census data). Information about deaths is
recorded in THIN in a specific field in an additional health file; for
this analysis an individual was accepted as dead if either there was
a record of date and cause of death or if a death certificate or other
external document confirmed the death.
Study population
In UK primary care, diagnoses are recorded using Read codes,
a hierarchical classification system that includes terms relating to
signs and symptoms, diagnosis, procedures and investigations [25].
Clinical diagnoses made by specialists and results from diagnostic
tests are entered retrospectively in general practice. Previous
studies have shown that the recording of cancer cases in THIN is
representative of cancer cases captured in other national statistics
[26,27]. For the current study, we identified all permanently
registered patients (aged 16 years or over)in THIN with a first
recorded diagnosis of lung cancer, colorectal cancer, or malignant
melanoma between 1997 and 2006 to allow us to examine survival
for a minimum of five years in all cancer cases as the availability of
latest data was to 31.12.2011, although follow up for earlier cases
is potentially much longer (up to 15 years). Read codes used to
identify cases of a diagnosis of each of the three cancers are
available on request.
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Statistical analysis
Rates of each of the three cancers were calculated by dividing
the number of cancer cases recorded by the number of person
years at risk. The denominator included all patients who had
contributed data after 1st January 1997, and rates were calculated
for the study period between 1997 and 2006. Gender-specific rates
are presented by age groups and quintiles of Townsend scores.
In the survival analysis, we used a Kaplan-Meier estimator to
compare men’s and women’s probability of survival over the 5
years following cancer diagnosis, and log-rank tests were used to
estimate survival difference in men and women. Since stage of
cancer is not reliably recorded in the THIN database, we
examined five year survival first in all patients with each cancer,
and then in the subset who had died at some time during follow-up
(minimum follow-up is five years, maximum follow-up is 15 years),
as a proxy for severity. Poisson Mixed Regression models are
applied to estimate gender differences in relative hazard of death
when age and socio-economic deprivation status were adjusted for,
and fitted survival models with time varying random effects
(defined by subject) to account for non linearity in relative hazards.
This analysis was applied to all cancer patients diagnosed between
1997 and 2006 and to the subset who died (all cause death) at
some time following cancer diagnosis.
We then identified all primary care contacts between clinicians
and patients diagnosed with CRC, lung cancer and malignant
melanoma between 1997 and 2006 within the 24 months
preceding their diagnosis. Consultation rates were calculated
using number of consultations recorded prior to diagnosis as the
numerator and the number of cancer patients as the denominator.
We compared consultation rates in men and women. A Poisson
regression model was used to estimate gender difference in
consulting rate prior to cancer diagnosis.
Analyses were conducted in Stata 12.
Results
1. Rates of cancer by gender
In total, between 1997 and 2006, 12,189 patients aged 16 years
or over were diagnosed with CRC, 11,081 patients with lung
cancer and 4,352 patients with malignant melanoma.
For colorectal cancer, 6,532 cases (54%) were diagnosed in men
(median age 71 years, interquartile range (IQR) 63–78) and
5,657(46%) in women (median age 74 years (IQR=64–81))
(Table 1). The overall rate of CRC cases recorded during the study
period was 68.30 (95% CI 66.66–69.85) per 100,000 person years
in men and 56.86 (95%CI 55.39–58.37) per 100,000 person years
in women. Rates of CRC cases rose with increasing age in both
men and women, and there was little gender difference in the rates
of CRC cases recorded before the age of 50, after which gender
differences increased. CRC rates were consistently higher in men
than women across all quintiles of Townsend scores.
Figure 1.Kaplan-Meier survival curves for colorectal cancer patients (diagnosed between 1997–2006).
doi:10.1371/journal.pone.0101562.g001
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The gender difference in the number of lung cancer cases
recorded between 1997 and 2006 was greater than that in CRC;
60% (n= 6,599) of recorded cases were men and 40% (n= 4,482)
were women. Median age at diagnosis was similar in men and
women (median age: M=72 years (IQR 64–78); F = 73 years
(IQR 64–79)). The overall rate of lung cancer cases recorded in
men was 68.77 (95%CI 67.12–70.46) per 100,000 person years
and 44.90 (95%CI 43.59–46.24) per 100,000 person years in
women. Lung cancer rates were higher in men than women in all
deprivation quintiles.
In contrast to CRC and lung cancer, more women (n = 2,491,
57%) than men (n= 1,861, 43%) had a recorded diagnosis of
malignant melanoma during the study period. Men were older
(median age 62 years, IQR=50–73) than women (58 years,
IQR=45–72) when first diagnosed. Between 1997 and 2006, the
overall rate of malignant melanoma cases recorded was 19.46
(95% CI 18.59–20.37) per 100,000 person years in men and 25.07
(95%CI 24.10–26.08) in women. More women were diagnosed
with malignant melanoma than men in younger age groups, but
more men were diagnosed amongst those aged 70 years and over
(Table 1). Rates were lower in men than in women across all
deprivation quintiles.
2. Survival time following cancer diagnosis by gender
Figure 1 shows Kaplan-Meier curves for survival by gender, first
for all those with a recorded diagnosis of CRC between 1997 and
2006, and secondly for the subset of cases who died (all cause
mortality) at some time during follow up. Amongst all cases,
gender differences in CRC survival to 5 years were relatively small;
49% of men and 53% of women survived at least 5 years following
cancer diagnosis (Figure 1, left). Women were more likely to have
survived after diagnosis (Chi-square, X2= 13.12, p = 0.003);
nonetheless, during the first three years following diagnosis the
survival curves for men and women were very similar. Amongst
the 3,497 (56%) men and 2,770 (44%) women who died at some
stage during follow-up, the Kaplan-Meier curves show that a
higher proportion of women than men died within the 1st, 2nd and
3rd year after cancer diagnosis (Figure 1, right). Within this
subgroup of CRC patients, the probability of survival was better in
men than in women (X2= 6.55, p = 0.0105).
As expected, survival to five years was poorer for lung cancer
patients than CRC patients: only 9% of men and 12% of women
with a recorded lung cancer diagnosis survived for 5 years or more
following diagnosis (Figure 2, left) and again differences in survival
between men and women were relatively small(X2 = 24.82, p,
0.001). There was negligible difference in survival to 5 years by
gender amongst the subset (5,427 (60%) men and 3,544 (40%)
Figure 2. Kaplan-Meier survival curves for lung cancer patients (diagnosed between 1997–2006).
doi:10.1371/journal.pone.0101562.g002
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women) who had died at some time over the whole follow-up
period, (Figure 2, right) (X2= 4.15, p = 0.0416).
Five year survival rates for patients with malignant melanoma
were substantially better than for CRC and lung cancer, although
fewer men (77%) than women (86%) survived at least 5 years
(Figure 3, left) (X2 = 52.58, p,0.001). However, amongst the
subset of 497 (55%) men and 403 (45%) women who had died at
some time over the follow-up period, there was no evidence of
gender difference in time to death up to five years following
diagnosis (Figure 3, right) (X2 = 0.01, p= 0.9360).
Table 2 shows the relative hazard of death (unadjusted, and
adjusted for age and deprivation status) amongst patients with
each cancer, before and after excluding patients whose dates of
death and diagnosis were on the same day, and before and after
excluding patients who were still alive. The adjusted male to
female hazard ratio of death in all patients was 1.20, 1.24 and 1.73
for colorectal cancer, lung cancer and malignant melanoma
respectively. Excluding patients whose date of diagnosis and death
were recorded as the same day made little difference to the hazard
ratios for CRC and lung cancer, but the hazard ratio increased for
malignant melanoma. However, amongst patients who died
during the follow up period, gender differences in the relative
hazard of death were close to unity for lung cancer and melanoma,
and 0.88 for CRC.
In summary, these analyses provide little evidence that men are
being diagnosed at a later stage, since the five year survival curves
do not differ greatly by gender (either in the complete patient
series or amongst the subset of patients who had died during
follow-up).
3. Primary care consultation preceding cancer diagnosis
Within the 24 months preceding cancer diagnosis, 11,787 out of
all 12,189 CRC patients diagnosed between 1997 and 2006 made
a total of 127,862 primary care consultations; 10,744 of all 11,081
lung cancer patients made a total 139,625 consultations; and 4,216
out of 4,352 malignant melanoma patients made a total of 37,687
consultations. Table 3 shows, for each of the three cancers, the
number and percentage of men and women who had consulted in
the periods 1–6 months, 7–12 months, 13–18 months, 19–24
months and 1–24 months prior to their recorded diagnosis. The
analysis was carried out first amongst all cancer cases diagnosed
between 1997 and 2006, and then for the subsample of cancer
patients who died at some time following diagnosis. The
consultation patterns were broadly similar in these two groups of
cancer patients, and therefore we present here the pattern
observed in all cancer patients. Results on consultation pattern
amongst the subset of cancer patients who died during follow up
are available on request.
Figure 3. Kaplan-Meier survival curves for malignant melanoma patients (diagnosed between 1997–2006).
doi:10.1371/journal.pone.0101562.g003
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For each cancer, there is little difference in the percentage of
men and women who consulted in the first six months prior to
their recorded cancer diagnosis, or in the 24 months prior to
diagnosis. However, a higher percentage of women than men
consulted in each of the six month time periods between 7 and 24
months prior to diagnosis, although these differences were often
relatively small (Table 3).
Table 4 shows the mean number of consultations made over the
same time periods prior to diagnosis. In the 24 months prior to
diagnosis, the mean number of consultations was a little lower for
men than women. Hence, for CRC it was 9.97 (95%CI 9.89–
10.04) in men and 11.09 (95% CI 11.00–11.18) in women; for
lung cancer it was 12.08 (95%CI 12.00–12.17) for men and 13.36
(95% CI 13.25–13.47) for women; and for malignant melanoma it
was 8.22 (95%CI 8.09–8.36) for men and 8.98 (95%CI 8.87–9.10)
for women. Moreover, there was little gender differences in mean
number of consultations was seen across each of the time periods
(maximum M:F ratio 0.99; minimum M:F ratio 0.90, table 4).
Table 5 presents the mean number of consultations in each
calendar month prior to cancer diagnosis by gender and cancer
site. In both men and women, the highest mean number of
consultations was in the month prior to the first record of the
cancer diagnosis.
Figures 4 to 6 presents mean number of consultations by gender
each month in the 24 months preceding diagnosis for CRC
(Figure 4), lung cancer (Figure 5) and malignant melanoma
(Figure 6) graphically. These clearly illustrate the lack of gender
difference in consulting prior to diagnosis.
In summary, these analyses suggest that whilst men consult a
little less than women prior to a diagnosis with CRC, lung cancer
or malignant melanoma, these differences are surprisingly modest.
Discussion
Our aim in this study was to assess whether there is evidence to
support the hypothesis that gender differences in patterns and
timing of consulting for symptoms of three non-sex specific cancers
(colorectal, lung and malignant melanoma) could plausibly
account for gender differences in mortality. We investigated
whether there were gender differences in survival following
diagnosis with these three cancers, and examined in particular
time to death in the first few years after diagnosis. We then
examined the number of GP contacts within the 24 months
preceding diagnosis by gender. Our analyses provide little
evidence that men are being diagnosed at a later stage than
women with these three cancers, since the five year survival curves
do not differ greatly by gender (either in the complete patient
series or amongst the subset of patients who had died during
follow-up). We have also shown that whilst men perhaps consult a
little less than women in the time periods 7–12, 13–18 and 19–24
months prior to a diagnosis with CRC, lung cancer or malignant
melanoma, these differences are surprisingly modest. In summary,
Table2. Estimation of the relative hazard of death for patients with colorectal cancer, lung cancer and malignant melanoma,
diagnosed 1997–2006.
Crude HR (95% CI) Adjusted HR1,2 (95%CI)
Colorectal Cancer
All patients (M/F) 1.09 (1.02 to 1.17) 1.20 (1.12 to 1.29)
p = 0.016 p,0.001
All patients, excluding those whose death is recorded as day of diagnosis3 1.12 (1.05 to 1.20) 1.21 (1.13 to 1.30)
P = 0.001 p,0.001
Patients with fatalities (died during follow up period) 0.86 (0.80 to 0.92) 0.88 (0.83 to 0.95)
p,0.001 p= 0.0004
Lung Cancer
All patients 1.24 (1.16 to 1.33) 1.24 (1.16 to 1.33)
p,0.001 p,0.001
All patients, excluding those whose death is recorded as day of diagnosis4 1.23 (1.15 to 1.31) 1.22 (1.15 to 1.30)
p,0.001 p,0.001
Patients with fatalities (died in during follow up period) 1.07 (1.01 to 1.14) 1.08 (1.01 to 1.15)
p = 0.0271 p= 0.0207
Malignant Melanoma
All patients 1.89 (1.64 to 2.18) 1.73 (1.51 to 1.99)
p,0.001 p,0.001
All patients, excluding those whose death is recorded as day of diagnosis5 2.19 (1.81 to 2.65) 1.93 (1.62 to 2.31)
p,0.001 p,0.001
Patients with fatalities (died in during follow up period) 1.04 (0.90 to 1.19) 1.04 (0.91 to 1.20)
p = 0.5999 p= 0.5325
1. adjusted for age (as continuous variable) and socioeconomic status.
2. including a generalized random intercept term for each patient to account for observed overdispersion.
3. 210 (3.2%) of men and 210 (3.71%) of women, p = 0.14.
4. 553 (8.4%) of men and 367 (8.2%) of women, p = 0.73.
5. 11 (0.6%) of men and 13(0.5%) of women, p = 0.84.
doi:10.1371/journal.pone.0101562.t005
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we contend that our analyses of these three non-sex specific
cancers provide little support for the hypothesis that gender
differences in mortality might be explained by men presenting
later or less often to primary care.
As expected, we found that more men than women were
diagnosed with colorectal cancer and lung cancer, but more
women with malignant melanoma (at least at younger ages). Our
results confirm some male disadvantage in relation to cancer, as
reported by others using different data sources [16,28,29]. There
was a small overall cancer survival advantage of females, which
remained when the analyses were adjusted for age and socio-
economic status. Amongst colorectal cancer patients, male to
female hazard of death increased slightly from 1.09 to 1.20 when
adjustment was made for age and social deprivation, perhaps
because women tend to develop colorectal cancer at an older age
compared to men [30–33].
Some studies have suggested that adjustment for stage of cancer
attenuates gender differences [34–37]. Since stage of cancer is not
reliably recorded in the THIN database, we identified a subgroup
of cancer patients who subsequently died after diagnosis, as a
proxy for patients with similar severity. Amongst these patients,
there was no evidence that men were dying earlier within the first
5 years after diagnosis, as we would have expected if they were
presenting, and being diagnosed, at a later stage of disease. For
CRC patients, the direction of gender disparities in the hazard of
death reversed from 1.20 amongst all CRC patients to 0.88 in the
subgroup who had subsequently died. Our finding that, for
colorectal cancer men in this subgroup were in fact better
survivors than women parallels findings from a German study
which reported better survival from advanced colorectal cancer in
men than in women, but better survival in patients with localised
cancers in women than men [36]. Likewise, a study of colorectal
cancer in Europe has reported a female to male relative risk of
death three years from diagnosis of 1.01 when adjusted for age,
gender, cancer site, stage and determinants of stage [38].
Variations in cancer survival may of course be explained both
by stage at diagnosis and quality of care following diagnosis.
It is still commonly asserted that men’s under-use of health
services and their tendency to ‘under-report’ health problems put
them at greater risk of dying from cancers [39], although there is
greater recognition that this is unlikely to be the case given the lack
of evidence to support the contention [40]. Another important
finding of this study is that differences in rates of consulting prior
to cancer diagnosis were negligible between men and women
diagnosed with these three non sex-specific cancers. This mirrors
results from our earlier study which noted that gender differences
Table 5. Mean number of primary care consultations per cancer patient (aged 16+) had in each month preceding their recorded
cancer diagnosis by gender.
Colorectal Cancer Lung Cancer Malignant melanoma
Mean no. of consultation/per cancer
patient consulted(95%CI)
Mean no. of consultation/per cancer
patient consulted(95%CI)
Mean no. of consultation/per cancer
patient consulted(95%CI)
Time prior to cancer
diagnosis M F M F M F
1 month 1.78 (1.75–1.82) 1.81 (1.77–1.85) 2.18 (2.14–2.22) 2.21 (2.16–2.25) 1.76 (1.69–1.83) 1.73 (1.67–1.79)
2 1.60 (1.56–1.64) 1.61 (1.56–1.65) 1.89 (1.85–1.94) 1.89 (1.84–1.94) 1.41 (1.33–1.49) 1.43 (1.36–1.50)
3 1.55 (1.51–1.60) 1.58 (1.54–1.63) 1.71 (1.67–1.76) 1.74 (1.68–1.79) 1.41 (1.32–1.51) 1.36 (1.29–1.44)
4 1.41 (1.37–1.46) 1.49 (1.44–1.54) 1.59 (1.54–1.64) 1.58 (1.53–1.64) 1.37 (1.27–1.47) 1.32 (1.25–1.41)
5 1.37 (1.33–1.42) 1.41 (1.36–1.46) 1.49 (1.44–1.54) 1.51 (1.46–1.57) 1.32 (1.23–1.43) 1.30 (1.22–1.39)
6 1.35 (1.30–1.40) 1.41 (1.35–1.46) 1.45 (1.41–1.50) 1.45 (1.40–1.51) 1.29 (1.18–1.40) 1.30 (1.22–1.39)
7 1.31 (1.26–1.36) 1.36 (1.31–1.42) 1.40 (1.35–1.45) 1.46 (1.40–1.52) 1.22 (1.12–1.33) 1.26 (1.18–1.35)
8 1.33 (1.28–1.38) 1.37 (1.32–1.43) 1.39 (1.34–1.45) 1.44 (1.39–1.50) 1.29 (1.19–1.40) 1.31 (1.23–1.40)
9 1.32 (1.27–1.37) 1.37 (1.32–1.43) 1.37 (1.32–1.43) 1.42 (1.36–1.49) 1.25 (1.15–1.35) 1.23 (1.15–1.32)
10 1.26 (1.21–1.31) 1.37 (1.32–1.43) 1.40 (1.34–1.45) 1.39 (1.33–1.45) 1.27 (1.17–1.38) 1.24 (1.15–1.32)
11 1.25 (1.20–1.31) 1.33 (1.28–1.39) 1.38 (1.33–1.44) 1.29 (1.23–1.35) 1.23 (1.13–1.34) 1.21 (1.12–1.29)
12 1.28 (1.23–1.34) 1.32 (1.27–1.38) 1.37 (1.31–1.42) 1.34 (1.29–1.41) 1.17 (1.06–1.27) 1.20 (1.12–1.29)
13 1.26 (1.21–1.31) 1.31 (1.25–1.36) 1.38 (1.33–1.44) 1.32 (1.26–1.38) 1.25 (1.14–1.36) 1.21 (1.13–1.30)
14 1.21 (1.16–1.27) 1.29 (1.24–1.35) 1.31 (1.26–1.37) 1.29 (1.23–1.35) 1.25 (1.15–1.37) 1.17 (1.08–1.26)
15 1.24 (1.19–1.30) 1.35 (1.29–1.41) 1.35 (1.29–1.40) 1.36 (1.30–1.42) 1.24 (1.14–1.35) 1.20 (1.11–1.29)
16 1.22 (1.16–1.28) 1.33 (1.28–1.39) 1.32 (1.26–1.37) 1.32 (1.25–1.38) 1.15 (1.04–1.26) 1.24 (1.16–1.33)
17 1.21 (1.16–1.27) 1.30 (1.24–1.36) 1.30 (1.24–1.35) 1.34 (1.28–1.41) 1.18 (1.07–1.30) 1.26 (1.16–1.35)
18 1.23 (1.18–1.29) 1.33 (1.27–1.39) 1.33 (1.28–1.39) 1.32 (1.26–1.39) 1.18 (1.07–1.29) 1.22 (1.13–1.30)
19 1.20 (1.15–1.26) 1.30 (1.25–1.36) 1.28 (1.23–1.34) 1.27 (1.21–1.34) 1.22 (1.11–1.33) 1.19 (1.10–1.28)
20 1.20 (1.15–1.26) 1.29 (1.23–1.35) 1.32 (1.26–1.38) 1.37 (1.30–1.43) 1.20 (1.09–1.31) 1.26 (1.17–1.36)
21 1.21 (1.15–1.26) 1.28 (1.22–1.34) 1.30 (1.25–1.36) 1.30 (1.24–1.37) 1.22 (1.10–1.34) 1.16 (1.07–1.26)
22 1.18 (1.12–1.23) 1.26 (1.20–1.32) 1.32 (1.26–1.38) 1.33 (1.27–1.40) 1.19 (1.08–1.31) 1.23 (1.13–1.32)
23 1.16 (1.10–1.22) 1.25 (1.19–1.32) 1.29 (1.23–1.35) 1.35 (1.28–1.41) 1.08 (0.97–1.20) 1.16 (1.07–1.26)
24 1.17 (1.11–1.23) 1.21 (1.16–1.28) 1.29 (1.24–1.35) 1.30 (1.24–1.37) 1.11 (1.01–1.23) 1.19 (1.10–1.29)
doi:10.1371/journal.pone.0101562.t004
Gender Difference and the Use of Health Service
PLOS ONE | www.plosone.org 9 July 2014 | Volume 9 | Issue 7 | e101562
Figure 4. Mean number of primary care consultations per colorectal cancer patient made prior to cancer diagnosis by month and
gender.
doi:10.1371/journal.pone.0101562.g004
Figure 5. Mean number of primary care consultations per lung cancer patient made prior to cancer diagnosis by month and
gender.
doi:10.1371/journal.pone.0101562.g005
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in the use of health services reduce considerably (to less than 10%),
when comparing men and women with similar underlying
morbidity [8]. We would argue that the marginal gender
differences in consulting shown in the current study strongly
challenge the hypothesis that gender differences in primary care
utilisation are an important explanation for gender differences in
longevity; they provide little support for an effect of gender on the
promptness of consulting [41]. Nonetheless, individuals’ pathways
prior to a cancer diagnosis are often not straightforward, and
patients vary in timing of their visits to medical professionals [42].
Both the number of consultations prior to cancer diagnosis and the
time from first symptom onset to first presentation to a GP have
been used in recent analyses as a measure of promptness of cancer
diagnosis [43,44], although these measures present different
challenges both for measurement and interpretation [44]. Keeble
and colleagues demonstrate that there is considerable variation by
cancer type in promptness of presentation amongst people
diagnosed with 18 types of cancers using data from the National
Audit of Cancer Diagnosis in Primary Care in England in 2009–
2010. They analyse ‘patient interval’ data (i.e. ‘‘the period between
first symptom onset and first relevant presentation to a doctor’’)
rather than ‘primary care interval’ data (i.e. ‘‘the promptness with
which general practitioners suspect the diagnosis of cancer and
refer patients to specialists’’) [44]. Prompt presentation was most
frequent for bladder and renal cancer and least frequent for
oropharyngeal and oesophageal cancer. However, their multivar-
iable analysis showed no evidence for variation in promptness of
presentation by gender and no evidence of interaction between
cancer diagnosis and gender. Another paper examining variation
in the number of GP consultations prior to a hospital referral for
cancer did find gender differences. This study utilised data from
the 2010 National Patient Cancer Experience Survey in England
to investigate which factors explained the considerable variation in
the number of GP consultations before hospital referral for 24
types of cancer. They reported that the probability of making three
or more pre-referral consultations was greater for women than
men (OR 1.28, 95% CI 1.21–1.36; p,0.001), and this was seen
for most of the 18 cancers occurring in both men and women with
a ‘‘few notable exceptions’’. The effect was particularly marked for
bladder cancer (OR 2.31, 95% CI 1.98–2.69). These findings thus
suggest that the ‘‘readiness of general practitioners to suspect
cancer’’ not only varies by cancer type, but also by gender; for
some cancers, particularly bladder cancer where there appears to
be a particular ‘‘danger of misattributing urinary tract symptoms
in women to a benign cause’’ (p363), women may ‘need’ to make
more visits to their GP before cancer is considered as the
underlying cause for reported symptoms [45]. These findings,
together with our own, suggest the need for further careful
investigation of gender differences in the responses of both patients
and health care professionals to the experience, reporting and
attribution of symptoms which could be indicative of an
underlying malignancy.
The strengths of our study include the use of a UK wide
primary care database and population-based electronic medical
records of cancer cases in general practice, the recording of which
are comparable to national cancer registry data [26,27]. None-
theless, the study has several potential limitations. First, there is the
lack of reliable information on cancer stage at diagnosis, as this is
rarely recorded on primary care systems. To address this limitation
we conducted our survival analyses both in all cancer patients and
in the subsample who had died during follow-up. In the latter
group there was no evidence of poorer male survival in the first
Figure 6. Mean number of primary care consultations per malignant melanoma patient made prior to cancer diagnosis by month
and gender.
doi:10.1371/journal.pone.0101562.g006
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few years following diagnosis, whilst we would have expected to
see a difference if men were being diagnosed at a later stage of
disease. Ideally, we would examine stage of disease directly.
Second, although age and deprivation were adjusted for in cancer
survival analyses, we were not able to examine to what extent
gender differences in cancer survival vary by factors such as
treatment and co-morbidities. Studies have found significant links
between co-morbidities and cancer outcomes amongst these three
cancers [46–48], and cancer survival may be influenced by gender
differences in co-morbidity at cancer diagnosis [49–52]. Third, our
relative hazard estimates of death were based on all cause deaths
rather than cancer specific deaths, as the recording of cause of
death is often incomplete in GP records [53]. Nevertheless, THIN
recording allows us to identify all deaths amongst people
diagnosed with these three cancers, irrespective of whether they
are directly or indirectly related to the cancer, not subject to bias,
providing a robust estimate of relative gender differences in cancer
survival. Finally, our analyses used GP recorded data on
consultations, but the content and nature of individual consulta-
tions is unknown. Although some of these consultations may have
been for other symptoms, arguably the patient’s attendance at the
doctor should present an opportunity for the doctor to detect
symptoms of cancer, irrespective of gender.
Conclusions
This large population-based study confirmed a relatively modest
disadvantage amongst men in five year survival from three non-sex
specific cancers compared to women in the UK. However,
amongst the subset of cancer patients who died during follow-up
there was very little difference in survival by gender. Furthermore,
patterns of consulting prior to cancer diagnosis differed little for
men and women, suggesting that gender differences in survival are
unlikely to be explained by gender differences in consultation for
these cancers at least. These findings thus challenge the still
common assumption that men delay seeking care for serious illness
and are being diagnosed at a later stage of disease leads to a poorer
prognosis and hence their higher overall mortality and reduced life
expectancy. Further research is needed to confirm whether this
holds for other types of cancer, and to understand the discrepancy
in cancer survival between men and women in order to prepare
the way for appropriate interventions to eradicate gender
inequalities.
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